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IntroductIon
Venous valves (VVs) are widely distributed throughout veins 
and venules and facilitate unidirectional blood flow back to 
the heart, which acts to reduce the peripheral venous blood 
pressure (Phillips et al., 2004; Bergan et al., 2006; Meissner et 
al., 2007). VV failure is a central feature of the venous reflux 
that is seen in up to 40% of adults. Reflux leads to chronic 
venous hypertension (particularly in the lower limbs), which 
can cause pain, edema, hyperpigmentation, skin damage, and 
chronic intractable ulceration (Bergan et al., 2006; Meissner 
et al., 2007). Our understanding of the molecular mechanisms 
of VV development and subsequent maintenance is limited, 
and there are few therapeutic options to treat VV dysfunc-
tion (Bergan et al., 2006; Bazigou et al., 2011; Caggiati and 
Caggiati, 2013; Munger et al., 2013, 2016; Maleti et al., 2015). 
Elucidation of these mechanisms and understanding of how 
their dysfunction may lead to VV failure could facilitate the 
development of novel therapies to treat this condition.
Clinical studies have suggested a link between venous 
reflux and primary lymphedema, but its cause (i.e., a direct 
VV defect or an indirect effect, such as vein dilatation) has not 
been elucidated (Rosbotham et al., 2000; Mellor et al., 2007; 
Ostergaard et al., 2011). We have previously shown how genes 
(Itga9, Efnb2, Fn-EII IA) regulating lymphangiogenesis also 
control VV formation and maintenance (Bazigou et al., 2011). 
Several transcription factors (Prox1, Foxc2, Nfatc1) and gap 
Venous valves (VVs) prevent venous hypertension and ulceration. We report that FoXc2 and GJc2 mutations are associated 
with reduced VV number and length. In mice, early VV formation is marked by elongation and reorientation (“organization”) 
of Prox1hi endothelial cells by postnatal day 0. the expression of the transcription factors Foxc2 and nfatc1 and the gap 
junction proteins Gjc2, Gja1, and Gja4 were temporospatially regulated during this process. Foxc2 and nfatc1 were coex-
pressed at P0, and combined Foxc2 deletion with calcineurin-nfat inhibition disrupted early Prox1hi endothelial organization, 
suggesting cooperative Foxc2–nfatc1 patterning of these events. Genetic deletion of Gjc2, Gja4, or Gja1 also disrupted early 
VV Prox1hi endothelial organization at postnatal day 0, and this likely underlies the VV defects seen in patients with GJc2 
mutations. Knockout of Gja4 or Gjc2 resulted in reduced proliferation of Prox1hi valve-forming cells. At later stages of blood 
flow, Foxc2 and calcineurin-nfat signaling are each required for growth of the valve leaflets, whereas Foxc2 is not required 
for VV maintenance.
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junction proteins (connexin [Cx]37, Cx43, and Cx47) have 
been implicated in the development of lymphatic valves (LV), 
cardiac valves, or VVs (de la Pompa et al., 1998; Winnier et 
al., 1999; Chang et al., 2004; Petrova et al., 2004; Norrmén 
et al., 2009; Kanady et al., 2011; Srinivasan and Oliver, 2011; 
Munger et al., 2013, 2016; Molica et al., 2014). Mutations in 
the genes encoding FOXC2, (FOXC2) CX47 (GJC2), and 
CX43 (GJA1) cause primary lymphedema in man (Fang et 
al., 2000; Ferrell et al., 2010; Ostergaard et al., 2011; Brice 
et al., 2013). Gjc2−/− and Gja4−/− (Cx37) mice have VV de-
fects during VV maturation, but the timing of onset of those 
abnormalities during VV formation and the developmental 
processes underlying absent VVs have not, to our knowl-
edge, been studied (Munger et al., 2013, 2016). Expression 
of Foxc2 and Nfatc1 is segregated to opposite leaflet surfaces 
during valve maturation, but their expression during VV 
initiation and potential cooperative signaling (as is seen in 
lymphatic endothelia) has not been studied (Norrmén et al., 
2009; Munger et al., 2016). Similarly, during leaflet matura-
tion Cx37 and Nfatc1 are not coexpressed in the same valve 
leaflet endothelial cells (ECs), but expression patterns in VV 
initiation remain undetermined (Munger et al., 2016).
In this study, we quantified the VV defects in the limbs 
of patients with primary lymphedema caused by mutations 
in GJC2 or FOXC2 and examined the earliest underlying 
mechanisms of VV failure caused by loss of those genes in 
mice. We identified reduced numbers of VVs and shorter VV 
leaflets in patients with lymphedema caused by mutations in 
FOXC2 or GJC2. In mice, we characterized the induction 
and organization of valve-forming ECs (VFCs), which occur 
at an earlier point than previously identified, and show that 
they occur within highly spatially and temporally regulated 
domains of Prox1, Foxc2, Nfatc1, Cx37, Cx43, and Cx47 ex-
pression (Bazigou et al., 2011; Munger et al., 2016). Com-
bined Foxc2 deletion and inhibition of Nfat signaling (but 
not Foxc2 deletion or Nfat inhibition alone) resulted in the 
failure of early VFC organization. Loss of connexin-encoding 
genes Gja1, Gjc2, or Gja4 similarly resulted in a failure of 
VFC organization, and for Gjc2 and Gja4, that resulted in re-
duced VFC proliferation. Both Nfat and Foxc2 signaling and 
blood flow were required for VV maturation to postnatal day 
6 (P6). Unlike its role in LVs, we show that Foxc2 is not re-
quired in VV ECs for valve maintenance (Sabine et al., 2015).
results
FoXc2, GJc2, and GJA1 mutations in human VV disease
Understanding the relationship between primary lymph-
edema and VV dysfunction has been hampered by our inabil-
ity to noninvasively quantify the presence and morphology 
of VVs in patients. Although VVs have been seen by ultraso-
nography, they have not been quantified on a systemic basis 
(Lane et al., 2007; Lurie and Kistner, 2012). We used conven-
tional ultrasonography to visualize VVs in humans (Fig. 1 A). 
Quantification was reproducible for the number of VVs/vein 
in repeated scanning by different operators (n = 28 veins, 
intraclass correlation coefficient = 0.90, 95% confidence in-
terval [CI] 0.63–0.91, P < 0.0005) and for leaflet length in 
repeated measurement by different operators (n = 15 VV, in-
traclass correlation coefficient = 0.94, 95% CI 0.83–0.98, P 
< 0.0005). This allowed quantification of the number of VVs 
Figure 1. Human VV phenotypes. (A) VVs (arrowheads) were visualized 
in controls and in patients carrying mutations in the indicated genes, with-
out (left) and with (right) power Doppler imaging of blood flow during a 
calf squeeze. An asterisk (*) marks stagnant/reversed flow in a VV sinus. 
Blood flow is from left to right. Bars, 1 mm. (B and C) Number (B) and 
length (C) of VV identified in patients carrying mutations in FOXC2 (n = 
8 patients), GJC2 (n = 3), GJA1 (n = 1), and healthy controls (n = 10). See 
Tables S1, S2, and S3. ***, P < 0.0005 (ANO VA with Bonferroni correction). 
Error bars represent means ± SEM. (D) Immunolocalization (arrowheads) 
of FOXC2 and CX43 in adult human VV leaflets. Bar, 20 µm. Mut, mutation.
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and VV leaflet length in the upper and lower limbs (Tables S1 
and S2). To limit scan duration, we scanned only the short sa-
phenous, popliteal, basilic, and brachial veins. Consistent with 
postmortem studies, different numbers of VVs (Tables S2 and 
S3) were detected in control veins (means ± SD, popliteal 1.1 
± 0.7; short saphenous 3.4 ± 1.5; brachial 1.8 ± 1.2; basilic 
2.4 ± 0.9, P < 0.0005, ANO VA) and, as expected, with differ-
ent leaflet lengths (popliteal 6.8 ± 1.9 mm; short saphenous 
4.0 ± 1.4 mm; brachial 3.9 ± 1.6 mm; basilic 4.9 ± 2.2 mm; 
P < 0.0005, ANO VA; Czarniawska-Grzesińska and Bruska, 
2002; Iimura et al., 2003; Schweighofer et al., 2010; Moore et 
al., 2011). Subsequent comparisons were therefore analyzed as 
the fold change relative to the respective vein in the controls.
We found significantly reduced numbers of VVs in 
patients with mutations in both FOXC2 (fold change ± 
SD 0.25 ± 0.32, P < 0.0005) and GJC2 (0.38 ± 0.46, P < 
0.0005; Fig. 1 and Tables 1 and 2) compared with age- and 
sex-matched controls. Those VVs that were present in the pa-
tients with FOXC2 or GJC2 mutations had shorter leaflets 
(0.44 ± 0.25, P < 0.0005 and 0.61 ± 0.28, P < 0.0005, re-
spectively). VV defects were present in the veins of both upper 
and lower limbs in patients for both FOXC2 and GJC2 (not 
depicted). There also appeared to be fewer VVs in the single 
patient identified with lymphedema caused by a mutation in 
GJA1 (CX43). Consistent with these findings, and in agree-
ment with their expression pattern in mouse VVs, FOXC2, 
and CX43 were localized on adult human VVs, suggesting that 
human VV phenotypes may result from tissue-autonomous 
effects of the patients’ mutations (Fig. 1 D). CX43 is predom-
inantly located on the lumen-facing leaflet surface, whereas 
FOXC2 is predominantly located on the sinus surface. We 
were unable to obtain typical, punctate CX47 staining using 
commercially available antibodies in human VVs (May et al., 
2013). It is possible that the Cx47 expressed in VVs during 
development and early life is subsequently down-regulated in 
the adult human VV, as has been found in mice for VEG FR3 
(Bazigou et al., 2011).
Imaging early VV development in mice
To investigate possible underlying mechanisms for these 
human phenotypes, we next analyzed VV development in 
mice and focused on the proximal femoral vein (FV) because 
of the critical role of proximal deep VV in human disease and 
because a VV most consistently develops at this position in the 
mouse, allowing reliable identification of the earliest stages in 
its development (Meissner et al., 2007; Bazigou et al., 2011; 
Eberhardt and Raffetto, 2014). We had previously analyzed 
opened veins (by electron and confocal microscopy), which 
damages VV structures and precluded analysis of the anterior 
vein wall and complete staging of VV development (Bazigou 
et al., 2011). We therefore used whole-mount confocal mi-
croscopy of unopened veins to visualize the proximal FV be-
fore and during VV formation.
Analysis from E17 to P6 revealed that initiation of VV 
formation occurs earlier than previously identified by im-
aging of opened veins or frozen sections (Fig. 2, A–C; Ba-
zigou et al., 2011; Munger et al., 2016). At E17, Prox1 was 
initially widely expressed throughout the FV (not depicted), 
with increased expression in a heterogeneous subset of ECs, 
termed “Prox1hi” cells (as in LV; Sabine et al., 2012; Sweet et 
al., 2015). These cells were distributed across the vein in the 
region of prospective VV formation (Fig. 2, C and D; stage 0 
of development). At P0, Prox1hi nuclei had undergone elon-
gation and reorientation and had organized to form a ring 
of VFCs around the vein (stage 1). Organization of VFCs is 
more prominent on the anterior wall of the FV, before full 
circularization (Fig. 2, F and G). This ring structure is the first 
time when the contiguous ring of spindle-shaped cells at the 
free edge of the valve leaflets (which is present throughout 
development and in adults) becomes identifiable. From that 
ring, a roughly circular leaflet develops toward the center of 
the FV, forming a marked constriction (stage 2). Part of the 
free-edge ring extends to the vessel wall to form the first 
commissure (stage 3). The free edge opposite that first com-
missure is not in contact with the vessel wall (see also Fig. S1 
A; BALB/c mice). This is followed by formation of a second 
commissure (stage 4). At earlier stages, smooth muscle cells 
uniformly coat the FV but subsequently become sparser in 
the region of the VV sinus (Fig. 2 E at P6).
Foxc2 and nfatc1 cooperate to pattern initial organization
The mechanism or mechanisms by which mutations in 
FOXC2 and GJC2 lead to defective VVs are unknown 
(Petrova et al., 2004; Mellor et al., 2007). We first analyzed 
the regulation of the initial ring of VFCs (stage 1), which 
forms by P0. Foxc2−/− mice do not survive to birth, so we 
investigated the effect of conditional deletion of Foxc2 using 
tamoxifen-inducible Cre recombinase under the control of 
Table 1. Mean number of valves in controls and patients
Group n VV/vein (normalized to control veins)
n veins analyzed Mean n VVs/vein SD
Control 68 1.00 0.53
FOXC2 64 0.25a 0.32
GJC2 24 0.38a 0.46
GJA1 8 0.63 0.41
Not all veins were scanned in all controls/patients.
aP < 0.0005 for FOXC2 and GJC2, for mean n valves (ANO VA with Bonferroni correction).
Table 2. Mean VV leaflet length in controls and patients
Group Leaflet lengths (normalized to control veins)
n VVs measured Mean leaflet length SD
Control 118 1.00 0.38
FOXC2 32 0.44a 0.25
GJC2 21 0.61a 0.28
GJA1 10 0.95 0.40
aP < 0.0005 for FOXC2 and GJC2, for mean leaflet length (ANO VA with Bonferroni 
correction).
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Figure 2. VV development in the proximal FV. (A and B) Micrographs before (A) and after (B) dissection to perform whole-mount imaging of the prox-
imal FV valve (boxed region). IVC, inferior vena cava; FA, femoral artery. Bar, 200 µm. (C) Localization of Prox1 (red), Foxc2 (green), and PEC AM1 (blue) at the 
indicated time points. An asterisk (*) marks single commissure at stage 3, and two commissures at stage 4. Arrowheads, reoriented and elongated VFCs. FE, 
free edge. Bars, 20 µm. n ≥ 6 VV/stage. (D) Corresponding schematics of stages in VV development: Prox1hi free-edge cells (red), leaflets (green), and leaflet 
attachment to the vein wall (blue). Arrows, blood flow direction. (E) A peri-VV reduction (between dotted lines) in SMA-expressing cells (red). Bar, 20 µm. n 
> 6. (F) Quantification of elongated Prox1hi valve cells on the anterior and posterior vein wall at P0. n = 9 (paired t test). (G) Arrowheads, anterior wall VFCs. 
Bar, 20 µm. Blood flow left to right in C–G.
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the Prox1 promoter (Prox1;CreERT2) in combination with 
floxed target alleles (Bazigou et al., 2011). Induction of Cre 
activity at E15 induced deletion in VV cells. However, neither 
heterozygous (Foxc2lx/+) or homozygous (Foxc2lx/lx) deletion 
produced a significant phenotype at P0 (Fig. 3 B). We there-
fore analyzed expression of the transcription factor Nfatc1, 
which is coexpressed with Foxc2 and is known to signal co-
operatively during lymphatic vessel maturation (Norrmén et 
al., 2009). At P0, Nfatc1 was colocalized with Foxc2 in Prox1hi 
VFCs and predominantly downstream of the forming valve 
(Fig. 3 A). Blocking Nfat signaling by homozygous deletion 
of the regulatory subunit of calcineurin (CnB1, encoded by 
Ppp3r1) in venous endothelium from E15, or administration 
of cyclosporin A (CsA; a well-characterized pharmacologi-
cal inhibitor of calcineurin-Nfat signaling) from E17 resulted 
in the expected cytoplasmic localization of Nfatc1 (Fig. S2, 
A–C) but had no effect on VFC organization at P0 (Fig. 3, 
C and D; Chang et al., 2004; Norrmén et al., 2009; Sabine et 
al., 2012). To simultaneously inhibit signaling through both 
transcription factors, we treated Prox1CreERT2;Foxc2lx/lx 
mice with CsA. Combined Foxc2lx/lx deletion and Nfat in-
hibition resulted in significantly abnormal VFC organization 
(Fig. 3 E). Thus, unlike LVs, only combined inactivation of 
Foxc2 and calcineurin/Nfat signaling was able to disrupt 
normal VV organization (Norrmén et al., 2009).
connexins pattern VV organization at P0
We next analyzed the expression of Cx37, Cx43, and Cx47 
at the earliest stages of VV development in the FV (Fig. 4, A, 
C, and E). At E18 Cx37 was immunolocalized to lymphat-
ics (not depicted) but was not detectable in the region of 
the FV where a VV subsequently always develops (Fig. S3 A). 
At P0 Cx37 was localized to VFCs, particularly in the upper 
and lower region of the vessel (Fig.  4  A). In Gja4 (Cx37) 
homozygous constitutive KO mice, initiation of VV forma-
tion at the usual location and the typical boundary between 
higher distal Prox1 immunostaining and higher proximal 
Foxc2 immunostaining was preserved. VFCs were identified 
distributed across the full width of the vessel but appeared 
highly disorganized, failing to reach stage 1, whereas all WT 
and heterozygous KO littermate VVs reached stage 1, as ex-
pected (Fig. 4 B). We next analyzed the junctions between 
VFCs by transmission electron microscopy (TEM) at P0 and, 
despite the rearrangements that these cells were undergoing, 
confirmed the appearance of gap junctions (inset in Fig. 4 G 
and Fig. S3, J and K). Although gap junction–mediated, inter-
cellular communication has been implicated in the regulation 
of Nfatc1 signaling in LV development in vitro, Nfatc1 im-
munolocalization remained nuclear in Gja4−/− mice, demon-
strating that Cx37 is not critically required upstream of Nfat 
nuclear translocation in VV, albeit Nfatc1hi nuclei were disor-
ganized (as seen with Prox1 immunolocalization; Fig. S3 D; 
Kumai et al., 2000; Sabine et al., 2012).
In contrast to Cx37, expression of Cx43 was not detect-
able on most VFCs but was instead localized to ECs upstream 
of those cells, with the strongest Cx43 immunostaining in 
the superior half of the upstream vessel (Fig. 4 C). It is pos-
sible that junctions consisting of Cx43 allow communica-
tion between this upstream region and VFCs in some areas. 
The source of Cx43 at junctions between these cells (either 
VFC or upstream endothelia) remains unclear. Homozygous 
conditional deletion of Gja1 (Cx43) resulted in the failure 
of organization of the VFCs downstream of that region, and 
VVs failed to reach stage 1, whereas WT littermates devel-
oped normally (Fig. 4 D).
Cx47 expression was studied using a Gjc2GFP (knock-in) 
reporter mice, with signal amplification using antibodies 
Figure 3. regulation of initial VV organization by Foxc2 and nfatc1. 
(A) Colocalization of Foxc2 (red) and Nfatc1 (green) in VFCs at P0. Foxc2 
and Nfatc1 localization are also shown separately. n = 4. Bar, 20 µm. (B–E) 
The proportion of VVs identified at stage 0 (white) and stage 1 (gray) at P0 
after deletion of Foxc2 (B) or Ppp3r1 (CnB1; C) from E15, or treatment with 
cyclosporin from E17 (D), or with combined Foxc2 deletion and cyclosporin 
treatment (E). The number of VVs analyzed for each condition is indicated 
above each bar. ***, P < 0.0005, χ2. (E) Localization of Prox1 (red) is shown 
at P0 after combined Foxc2 deletion and cyclosporin treatment. Bar, 20 µm.
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raised against GFP. Although no GFP signal was detected in 
the FVs of WT mice, expression was detected in cells dis-
persed throughout the FV in Gjc2GFP/+ mice (Fig. 4 E and 
Fig. S3, G and H) and Gjc2GFP/GFP mice (Fig. S3 I). Compared 
with WT littermates, Prox1hi VFCs showed a pattern of dis-
organization similar to loss of Gja4 and Gja1 at P0, but we 
could find very few VFCs expressing detectable Cx47 (GFP; 
Fig. 4 F), suggesting a non–VFC-autonomous role of Gjc2 in 
modulating VFC organization.
To further quantify the phenotypes resulting from loss of 
Cx37, Cx43, or Cx47, we first used Prox1CreERT2 crossed with 
the Rosa26mTmG reporter, in which membrane-targeted 
GFP is expressed in Cre-recombined cells, enabling us to show 
that nuclear morphology (orientation relative to the vessel and 
length/width ratio) can be used as a surrogate marker for cellu-
lar morphology in P0 VFCs (Fig. S4, A and B; Muzumdar et al., 
2007). We quantified Prox1hi nuclear elongation and reorienta-
tion as components of VV organization (Fig. 5 A). Elongation 
did not correlate with reorientation (Fig. S4 C), and we there-
fore analyzed these attributes separately. Elongated Prox1hi nu-
clei were significantly more reoriented in the central third of 
the vessel than in the upper and lower thirds (Fig. 5 A, right; 
and Fig. S4 D). We analyzed the proportions of Prox1hi nuclei 
in each region of the vein, where loss of Cx37 (but not Cx43 or 
Cx47) resulted in a reduced proportion of Prox1hi nuclei in the 
center of the vessel (Fig. 5 B). To quantify organization, we ana-
lyzed elongation and reorientation of nuclei within the central 
tertile, as previously described (Tatin et al., 2013). Loss of Cx37 
or Cx43 resulted in reduced nuclear elongation, whereas loss of 
Cx37, Cx43, or Cx47 resulted in reduced reorientation of the 
Figure 4. connexins pattern valve orga-
nization at P0. (A–F) Expression in WT mice 
(A, C, and E) and the KO or conditional dele-
tion loss-of-function phenotypes at P0 for 
Gja4, Gja1, and Gjc2 (B, D, and F). (A) Immu-
nolocalization of Cx37 (arrowheads), and (B) 
of Prox1hi VFCs (arrowheads) in Gja4−/− mice. 
Immunolocalization of Cx43 (arrowheads; C), 
and of Prox1hi VFCs (arrowhead; D) in Prox-
1CreERT2;Gja1lx/lx mice after induction of de-
letion at E15. (E and F) Immunolocalization 
of GFP (green, arrowheads in E) in Gjc2GFP/+ 
reporter mice (E), and of Prox1hi VFCs (arrow-
heads in F) in Gjc2GFP/GFP KO mice (F). n ≥ 6 for 
all images. Bars, 20 µm. Blood flow is from 
left to right throughout. Graphs in B, D, and F 
show the proportion of VVs identified at stage 
0 (white) and stage 1 (gray) at P0 for the indi-
cated genotypes, and number of VVs analyzed 
for each condition is given above each bar. *, 
P < 0.05; **, P < 0.005; χ2/Fisher’s exact test. 
(G) A tiled TEM image of the junction between 
two adjacent, free-edge cells at P0, shown at 
lower magnification in Fig. S3 K. n = 3. Bars: 
100 nm; 10 nm in inset.
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nuclei (Fig. 5; data for all genotypes and vessel regions analyzed 
are provided in Fig. S4 E). Together, these data show that Cx37, 
Cx43, and Cx47 are each critical for the cellular reorganization 
that occurs to reach stage 1 of VV development.
To determine whether connexin loss resulted in failed 
proliferation of VFCs, we analyzed the proportion of Prox1hi 
VFCs colabeled with Ki-67. This revealed reductions in 
the proportion of proliferating VFCs in both Gja4−/− and 
Figure 5. Quantification of connexin phenotypes. (A, left) The schematic indicates how position and orientation of Prox1hi VFCs were measured in the 
middle and right panels. (Middle) Binned scatterplot of VFC elongation (length/width ratio) across the vein from superior (tertile 3) to inferior (tertile 1). n 
= 1,388 cells; 17 VVs. The red dotted box indicates elongated nuclei (length/width ratio ≥2), which were further analyzed in the right panel. (Right) Binned 
scatterplot of elongated VFC nuclear reorientation across the vein. The blue dotted box indicates nuclei rotated ≥40°. n = 953 cells; 17 VVs. (B) The propor-
tion of Prox1hi VFCs in the middle tertile is shown for the indicated genotypes.**, P < 0.005; t test. (C) The elongation of Prox1hi nuclei from the central tertile 
of valves of the indicated genotypes is shown. Elongated nuclei (length/width ratio ≥2) are highlighted in red. (D) The reorientation of elongated Prox1hi 
nuclei from the central tertile of valves of the indicated genotypes is shown. Reoriented nuclei (≥40°) are highlighted in blue. *, P < 0.05; **, P < 0.005; χ2. 
(B–D) n = 6 WT versus 8 Gja4−/− VVs; 6 WT versus 10 Gja1lx/lx VVs; 5 WT versus 5 Gjc2−/− VVs. Data for all genotypes and vein regions provided in Fig. S4. 
(E) Graphs indicate the mean number (as fold over WT littermate VVs) of Prox1hi;Ki-67+ proliferating VFCs for the indicated genotypes. n = 5 WT versus 
6 Gja4−/− VVs; and 6 WT versus 6 Gjc2−/− VVs. **, P < 0.005; ***, P < 0.0005; t test. (F) Representative images are shown of Prox1 (red) and Ki-67 (green) 
immunolocalization in the upper region of the valve in Gja4−/− and Gjc2−/− mice and a WT littermate. Arrowheads indicate Prox1- and Ki-67–coexpressing 
cells. Bar, 10 µm. Images are a 6-µm-thick z-projection of 0.5-µm optical sections.
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Gjc2GFP/GFP mice (P < 0.0005 and P < 0.005, respectively; 
Fig. 5, E and F). We could find no evidence of apoptotic VFCs 
in either of these KO lines (not depicted).
Maturation of leaflets and commissures
We next analyzed the maturation of VVs to P6, and asked 
whether Foxc2 or calcineurin-Nfat signaling is required for 
development of VV leaflets and commissures. In contrast 
to their cooperative roles in patterning the initial VV ring, 
calcineurin inhibition with CsA (Fig.  6  A), loss of CnB1 
(Ppp3r1lx/lx deletion) at P0 (Fig. 6, B and C), or deletion of 
Foxc2 alone (Fig. 6 D) were each sufficient to cause signif-
icant defects in leaflet/commissure development through to 
stages 3–4. There was no loss of the ring of rotated Prox1hi 
free-edge cells, which remained intact even at P6 (Fig. 6, A 
and B), demonstrating that neither Nfatc1 signaling or Foxc2 
are required for maintenance of this initial valve structure and 
the free-edge phenotype of these cells.
Cx37 remained expressed in VV leaflets at P6 (Fig. 6 E). 
Unlike the phenotype seen with loss of Ppp3r1, Foxc2, and 
to some extent, Itga9 or Efnb2 (Fig. S5), analysis of Gja4−/− 
VVs at P6 revealed complete absence of both leaflet structure 
and Prox1hi or Foxc2hi cells (Fig.  6  F), demonstrating that 
the early development of VV seen at P0 in Gja4−/− (Cx37) 
Figure 6. Maturation of leaflets and commissures. (A) Immunolocalization at P6 of Nfatc1 (green) and Prox1 (red) in VV of WT mice administered 
control solvent or cyclosporin (n = 5 versus 8 VVs, P < 0.05, χ2). (B) Immunolocalization of Foxc2 (green) and Prox1 (red) in VVs of mice of the indicated 
genotypes. n ≥ 6 per condition. (C and D) Quantification of leaflet length and stage of VV development in mice of the indicated genotypes. Error bars repre-
sent means ± SEM. t test for leaflet length. (C, D, G, H, and I) Colors represent developmental stage (see key). The number of VVs analyzed for each condition 
is given above each bar. *, P < 0.05; **, P < 0.005 (χ2 for developmental stage). (E) Immunolocalization of Cx37 (arrowheads) and Cx43 in VV leaflets at P6. 
n ≥ 4. (F) Localization of Prox1, Foxc2, and SMA at P6 in Gja4−/− vein. n ≥ 6 (G and H) Stages of VV development reached in mice of the indicated genotypes. 
(I) Localization of Prox1, GFP, and SMA in Gjc2GFP/GFP KO reporter vein at P2 (n = 4), and stages of VV development reached in mice of the indicated genotypes. 
(J) Localization of Cx47-expressing VV cells (arrowheads) of Gjc2GFP/+ reporter mice at P6. n = 4. Multichannel images are reproduced in supplementary data. 
Bars, 20 µm. (A–J) Blue stain is PEC AM1.
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mice is subsequently lost, and Cx37 is required to maintain 
the free-edge cell phenotype. This was associated with failure 
to form the gap in smooth muscle actin (SMA)–expressing 
cells normally seen around the valve (Fig. 6 F). As expected, 
VV in Gja4+/− mice developed normally (Fig. S5 G). These 
results are consistent with previously reported findings 
in LVs and with the absence of VVs at P4 in Gja4−/− mice 
(Munger et al., 2013, 2016).
At P2, Cx43 was barely detectable in VV leaflets (Fig. S5 
H), but at P6, it was clearly localized around Nfatc1-expressing 
ECs (Fig. 6 E). Conditional, homozygous Gja1 deletion from 
P0 did not produce a significant phenotype at P6, suggesting 
that the critical requirement for Cx43 in VV development is 
restricted to events before or around P0 (Fig. S5 I).
GFP-expressing cells were almost entirely undetectable 
in Gjc2GFP/+ VVs at P2 (Fig. S5 K), but by P6, Cx47-expressing 
cells were clearly detected within the valve (Fig. 6 J). In con-
trast, Gjc2GFP/GFP mice (lacking Gjc2 expression) had no valve 
cells by P2, indicating loss of the Prox1hi phenotype seen at P0. 
These results suggest that the critical requirement for Cx47 is 
restricted to events around P0 (Fig. 6 I and Fig. S5 L) and are 
in agreement with previous findings of absent VVs in femoral 
and other veins analyzed at later postnatal stages in Gjc2−/− 
mice (Munger et al., 2016). Notably, Cx47 is not required 
for the development of valves in all veins (e.g., the superfi-
cial caudal epigastric or proximal subclavian veins), consistent 
with our finding of ∼40% VVs remaining in peripheral veins 
of patients with mutated GJC2 (Munger et al., 2016).
A role for blood flow in VV development
Because several genes required for VV development, includ-
ing Foxc2 and Gja4 (Cx37), are up-regulated by fluid shear 
stress, we hypothesized that blood flow may be required for 
normal VV leaflet growth (Sabine et al., 2012; Sweet et al., 
2015). To alter blood flow across the developing VV, we li-
gated and divided the FV at P0, and analyzed the VV at P6. 
No thrombosis was seen, and pups operated on gained weight 
normally (P > 0.05 vs. unoperated littermates). We initially 
ligated the FV at P0 (Fig. 7 A), which did not result in visible 
diversion of blood flow (likely because of the small collaterals 
seen at the site of the ligation; not depicted), and valve de-
velopment was unaffected. We then ligated the FV twice and 
divided the FV (Fig. 7 B), resulting in rerouting of blood via 
collaterals, with flow past the main valve region seen to re-
enter via those collaterals (Fig. 7 B). VVs exposed to those al-
tered flow conditions showed reduced progression to the later 
stages of leaflet development compared with VVs exposed to 
unaltered flow conditions on the unoperated, contralateral 
side (Fig. 7 B) and were smaller (Fig. 7 C).
regulation of VV maintenance
Because patients with heterozygous FOXC2 mutations 
showed severe VV defects, and Foxc2 is required for LV main-
tenance, we next asked whether Foxc2 was also needed for 
VV maintenance as well as development (Sabine et al., 2015). 
Induction of deletion in Foxc2lx/lx mice at 4 wk resulted in 
absent Foxc2 immunosignal 4 d later (not depicted), but in-
terestingly, VV length at 6 wk (Foxc2lx/+ or Foxc2lx/lx) or 28 
wk (Foxc2lx/+) was similar to littermate controls (Fig.  7, D 
and E), demonstrating that EC Foxc2 expression is not re-
quired for VV maintenance at the timepoints analysed.
dIscussIon
We have identified profound structural VV defects in patients 
carrying mutations in the genes encoding the transcription 
factor FOXC2 and the gap junction protein CX47. Crucially, 
we have extended our understanding of VV development in 
mice to the earliest endothelial events and have identified a 
temporospatially regulated pattern of transcription factor and 
gap junction protein expression around Prox1hi VFCs. This is 
required for the organization of an initial ring of VFCs that 
is then critical for ongoing VV development. Using a ge-
netic loss-of-function approach combined with drug inhib-
itors, we have demonstrated requirements for Cx37, Cx43, 
and Cx47 and provided evidence for Foxc2–Nfatc1 coop-
erative signaling in the regulation of VFC organization at P0. 
At later stages, we show requirements for Foxc2 and calci-
neurin–Nfat signaling and blood flow in regulating the mat-
uration of valve leaflets.
Human VV phenotypes
Valve defects were particularly severe in patients with FOXC2 
mutations, with 75% fewer valves, and remaining valves were 
almost half the length of valves in matched controls. This 
finding is consistent with the increased incidence of chronic 
venous insufficiency that we have previously identified in 
this group of patients (Brice et al., 2002; Mellor et al., 2007). 
Patients with mutations in GJC2 had 62% fewer valves, and 
those present were substantially shorter than those seen in 
controls. Again, this is consistent with the studies of incom-
petent veins in those patients (Ostergaard et al., 2011). The 
human GJC2 mutations studied here produce an aa substitu-
tion in the first extracellular loop (which may affect connexin 
docking) and one in the intracellular loop (Ostergaard et al., 
2011; Molica et al., 2014). The mutation in GJA1 (Cx43) re-
sults in a substitution (K206R) in the highly conserved SRP 
TEK motif of the second extracellular loop and may exert 
dominant negative effects on connexin docking, gap-junction 
function, and levels of WT protein (Brice et al., 2013; Mol-
ica et al., 2014). The finding of fewer VVs in a single patient 
(albeit without statistical significance) is consistent with the 
VV developmental defects seen in mice after Gja1 dele-
tion and requires exploration as further patients with GJA1 
mutations are identified.
transcriptional regulation of mouse VV formation
Our studies in mice extend previous descriptions of VV de-
velopment, with our analysis of intact veins showing that ini-
tial events in VV formation occur earlier than we and others 
have previously identified (Bazigou et al., 2011; Munger et al., 
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2013, 2016). We also show that valve development is affected 
by the background of the mouse strain used (Fig. S1).
In lymphatic endothelium, Foxc2 and Nfatc1 are coex-
pressed, physically interact, and signal cooperatively to pattern 
vessel maturation (Norrmén et al., 2009). We examined prox-
imal whole-mount vein samples and found that Foxc2 and 
Nfatc1 were coexpressed by VFCs and endothelium down-
stream of the organizing VFCs. We report that although nei-
ther endothelial Foxc2 or calcineurin–Nfat signaling alone 
is required for organization of initial valve-ring patterning, 
combined inhibition of Nfat signaling and Foxc2 deletion re-
sults in complete disorganization of the valve-forming region. 
This leads us to suggest that there is a degree of redundancy 
in regulation at this point. It is difficult to fully exclude the 
possibility that a very low level of Foxc2 protein or calci-
neurin–Nfat signaling remained after Foxc2/Ppp3r1 deletion 
and inhibition of Nfat signaling. However, we could find no 
Foxc2 immunosignal present in VVs 4 d after induction of 
deletion (unpublished data) in 4-wk-old mice, suggesting 
that Foxc2 depletion in VVs was efficient. In our experi-
ments, we either deleted Ppp3r1 (CnB1) or administered 
CsA. Although we did not observe specific staining in devel-
oping VVs using antibodies raised against Nfatc2, Nfatc3, or 
Nfatc4 (unpublished data), we cannot fully exclude possible 
roles for these proteins.
connexins pattern VFc organization
Although variation in connexin expression in veins at P0 has 
recently been reported, the expression was not related to posi-
tioning at the sites of VV formation, which was not described 
until P4, when VV leaflets are already maturing (Munger et al., 
2016). Here, whole-mount techniques enabled us to demon-
Figure 7. role of blood flow in valve growth and the regulation of VV maintenance. (A and B) Representative images at P0 and P6 after single FV 
ligation (arrowheads in A) or double ligation and FV division (arrowheads in B) at P0, and quantification of the proportion of valves reaching each develop-
mental stage at P6 in VVs of operated and unoperated limbs. The number of VVs analyzed is given above bars. An asterisk (*) indicates collateral vessel. Bars, 
500 µm. **, P < 0.005, χ2. Dotted boxes X and Y indicate regions examined by immunofluorescence at P6. In X, arrowhead indicates suture, and the arrow 
shows the remodeling FV. In Y, the asterisk (*) indicates large collaterals, and the arrow shows the proximal FV. Bars, 20 µm in micrographs. (C) Localization 
of Foxc2 (green) and quantification of VV area in VV exposed to reduced flow (n = 8) and controls (n = 12). ***, P < 0.0005, t test. Bar, 20 µm. (D and E) Anal-
ysis of VV length (Hematoxylin-eosin) at 2 wk (D) and 24 wk (E) after Foxc2 deletion. P = NS (ANO VA). The number of VVs analyzed is given below each bar.
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strate that expression of Cx37, Cx43, and Cx47 is specifi-
cally temporospatially regulated relative to VFCs at an earlier 
stage, between E18 and P0. Although Cx37 was expressed by 
Prox1hi VFCs, Cx43 and Cx47 were predominantly expressed 
by cells upstream of the VFCs, rather than by VFCs them-
selves. Despite that, loss of Gja1, Gjc2, and Gja4 all resulted in 
failure of organization of the early Prox1hi VFCs, character-
ized by loss of Prox1hi elongation and reorientation. Cx37 loss 
resulted in a lower proportion of VFCs in the central portion 
of the vein, but that was not seen for loss of Cx43 or Cx47. 
Loss of Cx37 or Cx47 resulted in reduced VFC proliferation. 
It remains unknown whether this is a direct effect of the loss 
of gap junctions or because of the failure of VFCs to organize 
normally, which could lead to reduced cell–cell signaling and 
loss of reinforcement of VFC identity. The loss of proliferation 
seen with Gja4 KO is surprising because in other settings loss 
of Cx37 was associated with increased proliferation (Burt et 
al., 2008; Morel et al., 2010; Kanady et al., 2015). Although 
we did not detect apoptotic VFCs, we cannot exclude the 
possibility that any apoptotic cells were rapidly washed down-
stream. Collectively, our data suggest that in the setting of VVs 
it may be a failure of Prox1hi cell organization (and resulting 
breakdown of inter-VFC communication) that results in the 
subsequent failure of further valve development in these mice.
Our TEM analysis of cell–cell junctions between 
free-edge (Prox1hi) VFCs at P0 shows the presence of gap 
junctions. It is possible that groups of ECs could develop dis-
crete regions of gap-junction intercellular communication, 
for example, upstream of the initial Prox1hi ring (Cx43, Cx47) 
or between free-edge cells themselves (Cx37), allowing for 
patterning of development by restricted regional endothelial 
signal propagation (Tallini et al., 2007; de Wit and Griffith, 
2010; Pfenniger et al., 2012). Regional variations in endothe-
lial connexin expression have important roles in cardiac valve 
formation, for example, patterning of the transcriptional ac-
tivity of Nfatc1 by Cx45 in endocardial-cushion ECs (where 
deletion of Cx45 abrogated Nfatc1 signaling; Kumai et al., 
2000). Sometimes connexins have roles entirely independent 
from intercellular communication. For example, Cx43 mod-
ulates cell polarity and directional cell migration (Francis et 
al., 2011). Although this cell-autonomous role could not en-
tirely explain the disorganization of VFCs because we could 
find no Cx43 in most of those cells at P0, Cx43 loss could 
disrupt behavior of ECs immediately upstream of the Prox1hi 
cells. The population(s) of cells contributing to VV have not 
been defined and could include contributions from that up-
stream region, for example, by becoming leaflet ECs or by 
communicating with valve cells to regulate their behavior. 
Interpretation of connexin phenotypes is further complicated 
by the formation of heteromeric and/or heterotypic channels 
(Goodenough and Paul, 2009; Molica et al., 2014).
Patterning of valve position
Despite the Prox1hi disorganization phenotype seen with loss 
of Gja1, Gjc2, and Gja4, VFCs were nonetheless located at 
the normal site of VV formation, and in a broad region across 
the vessel, suggesting that other factors are responsible for the 
positioning of the VV along the vein, the initial VFC speci-
fication, and for the overall patterning of that initial ring of 
VFCs. The finding of roles for Gja1 and Gja4 in patterning 
VFC reorientation and elongation at P0 is consistent with 
both the molecular similarity between VVs and LVs that we 
previously reported (Bazigou et al., 2011) and previous stud-
ies of absent VVs in Gja4−/− and Gjc2−/− mice identified at 
later ages (Munger et al., 2013, 2016).
regulation of leaflet maturation and maintenance
Our data indicate differential requirements for maintenance 
of the free-edge cells during later development beyond P0. 
To more accurately assess the VV phenotype seen with loss of 
Itga9 and Efnb2, we performed whole-vein confocal imaging 
of mice with postnatal deletion of Itga9 and Efnb2 induced 
from P0 (Bazigou et al., 2011). As expected, at P6 a severe 
phenotype was seen in both mutants with complete loss of 
VV leaflets but with some residual Prox1hi VFCs remaining 
(Fig. S5, A–C; Bazigou et al., 2011). By comparison, valve cells 
were completely absent at P2 with loss of Cx47, and at P6 
with loss of Cx37. This phenotype was more severe than that 
identified with loss of integrinα9, ephrin-B2 (when many 
Prox1hi cells remained) or CnB1 (when a strikingly complete 
VFC ring remained). This restricts the requirement for Nfatc1 
to extension of the VV leaflets and not to maintenance of VFC 
identity. Our results suggest that Cx37 and Cx47 are required 
for the early stability of the VFC ring phenotype, as has pre-
viously been suggested for Cx37 in LVs (Sabine et al., 2012). 
These results are also in accordance with a study of failed in-
vagination of lymphovenous valves in Gja4−/− mice (Geng et 
al., 2016). Cx37 remains highly expressed by VVs and may ad-
ditionally be required for VV maintenance. In Gjc2GFP/+ mice, 
Cx47-expressing cells were clearly identified at P6, suggesting 
that Cx47 could also have ongoing roles in maintenance. De-
lineation of possible roles for Cx37 and Cx47 after P0 will 
require a conditional loss-of-function approach. The role of 
Cx43 was examined by conditional deletion in ECs, and we 
found that connexin was required for early but not later stages 
of valve development. Gja4−/− and Gjc2GFP/GFP mice failed to 
develop an area of reduced SMA-expressing cells around the 
valve, most likely secondary to loss of the valve ECs (Bouvrée 
et al., 2012; Jurisic et al., 2012).
Calcineurin–Nfat signaling was critical for leaflet elon-
gation and commissure formation, consistent with its require-
ments for leaflet growth in the aortic valve and LVs (Johnson et 
al., 2003; Chang et al., 2004; Sabine et al., 2012). Conditional 
homozygous deletion of Foxc2 similarly produced a pheno-
type during leaflet maturation. In contrast to the requirement 
for Foxc2 in LV maintenance (Sabine et al., 2015), we found 
that Foxc2 was not important for VV maintenance during the 
time frame investigated. The timing of the onset of VV failure 
in patients with FOXC2 mutations is unknown; further work 
should explore whether VVs in those patients develop nor-
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mally and later regress or fail to develop at all. We speculate 
that other transcription factors (e.g., FOXC1) could regulate 
VVs and compensate for loss of FOXC2 (Fatima et al., 2016).
the role of blood flow
The regulators of Cx37, Cx43, and Cx47 in VV formation 
remain unclear. In vitro and in vivo experiments indicate 
that Foxc2 regulates expression of Cx37 in lymphatic endo-
thelium (Sabine et al., 2012; Munger et al., 2013). Although 
both are expressed by VFCs, the lack of VFC phenotype seen 
after Foxc2 deletion suggests that other factors can compen-
sate for the loss of Foxc2 in these cells at P0. (Munger et 
al., 2013; Kanady et al., 2015). For example, Klf2 regulates 
Cx37 expression in blood endothelium in regions exposed 
to high laminar shear stress (Pfenniger et al., 2012). Alterna-
tively, induction of a GATA2/Foxc2/Prox1 pathway by oscil-
latory shear has been proposed as a mechanism for initiation 
of LV formation (Sabine et al., 2012; Kazenwadel et al., 2015; 
Sweet et al., 2015). GATA2 is expressed by venous VFCs (un-
published data), and a similar process may regulate VV initi-
ation. The early protrusion of VFCs into the lumen and the 
associated shear exposure may provide a further mechanism 
to regulate expression in those cells. Our finding of smaller, 
less-developed VVs after reduction in blood flow through the 
FV (albeit during VV maturation, not initiation) is consistent 
with that concept. We cannot confirm, however, that the ef-
fect is valve specific rather than a general effect on EC growth.
conclusions
Patients with mutations in FOXC2 and GJC2 have globally 
reduced numbers of VVs and shorter VV leaflets. Foxc2 and 
calcineurin–Nfatc1 signaling cooperate to organize the initial 
ring of VV-forming cells. Cx37, Cx43, and Cx47 are critical 
for early organization of VFCs at P0, and failure of this pro-
cess likely underlies abnormal VVs identified in patients with 
mutations in GJC2. Foxc2 expression in valve ECs is not re-
quired for VV maintenance.
MAterIAls And MetHods
All human and animal studies were performed in accordance 
with national regulations and ethical approvals (National 
Research Ethics Service Committee, South East Coast 10/
H0701/68, 12/LO/1164, and the UK Home Office).
VV ultrasonography
The following veins underwent ultrasonographic evaluation: 
the brachial (antecubital fossa to axillary vein; medial brachial 
vein, if paired), basilic (antecubital fossa to axillary), popliteal 
(adductor hiatus to trifurcation), and short saphenous (saphe-
nopopliteal junction, if within 10 cm of the knee skin-crease, 
to 20 cm below the knee). Veins were visualized along their 
entire length, switching between longitudinal and transverse 
views to detect VVs, using a Philips Healthcare IU22 ultra-
sound machine with L17-5MHz/L9-3MHz probes. Partici-
pants with any history of deep vein thrombosis were excluded 
as were ablated or operated veins. Images and cine loops were 
recorded of each VV in B mode and with color Doppler. VV 
maximum leaflet measurements were obtained offline (Xcel-
era catheterization laboratory software; Philips Healthcare). 
For each vein, the number of VVs and VV length was normal-
ized to the mean value in the respective control veins.
Human genotyping
The screening of patient with FOXC2 mutations was per-
formed by the South West Thames Regional Genetics Ser-
vice at St George’s Hospital, University of London. Screening 
for GJC2 and GJA1 mutations was performed as previously 
described (Ostergaard et al., 2011; Brice et al., 2013).
Mouse lines
In brief, BALB/c, MF1, FVB, C57BL/6, and CD1 WT mice 
were obtained from Charles River UK. WT analyses were 
performed in BALB/c mice, unless indicated. Prox1CreERT2 
(Bazigou et al., 2011), Foxc2lx (Sasman et al., 2012), Gja4−/− 
(Simon et al., 1997), Gjc2GFP (Odermatt et al., 2003), Gja1lx 
(Calera et al., 2006), pp3r1lx (Zeng et al., 2001), and Rosa-
26mTmG (Muzumdar et al., 2007) mice have been described 
previously and were maintained on C57BL/6 backgrounds, 
except for Prox1CreERT2;Foxc2lx, which was back-crossed 
onto BALB/c mice. For the induction of Cre activity in 
Prox1CreERT2 mice, tamoxifen/4OH–tamoxifen (in sun-
flower oil; Sigma-Aldrich) was injected i.p. with either 5 mg 
at E15 for analysis at P0, or 50 µg at P0 for analysis at P6 (Ba-
zigou et al., 2011). 37.5 µg/g mouse weight progesterone was 
given i.p. at E15 + E18, and embryos were analyzed at “E19” 
(equivalent to P0). In all experiments, we compared VVs in 
Prox1CreERT2+ with Prox1CreERT2− littermate controls. 
For drug inhibition of Nfat nuclear translocation, 50 µg/g 
mouse weight CsA (EMD Millipore) was administered i.p. 
twice per day at P1–P6, and VVs were analyzed at P6. For 
combined deletion of Foxc2 and calcineurin inhibition, de-
letion was performed from E15, and CsA at 50 µg/g mouse 
weight i.p. twice per day from E17 to E19. For induction of 
deletion at 4 wk, mice received 1 mg Tam i.p. once per day 
for 2 d. For flow alteration at P0, pups were anaesthetized 
(Univentor 4000) with isoflurane, and the femoral artery and 
vein (which are inseparable at P0) were ligated (10/0 vicryl), 
and the vein was divided before closure (10/0 vicryl); postop-
erative care was provided with the mother.
electron microscopy
For TEM, P0 pups were culled and perfused via the aorta 
with heparinized PBS (hPBS; 25 mg/liter; MP Biomedicals) 
before fixation overnight in glutaraldehyde (2.5% vol/vol 
in 0.1  M cacodylate buffer, pH 7.4, 4°C) and postfixation 
in osmium tetroxide (1% wt/vol in 0.1  M cacodylate, pH 
7.4, 4°C) for 1.5 h. For visualization of mouse gap junctions, 
samples were immersed in 1% osmium tetroxide: 1.125% po-
tassium ferrocyanide for 1 h, followed by en block staining 
with 1% aqueous uranyl acetate. All samples were dehydrated 
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through graded ethanols, equilibrated with propylene oxide, 
infiltrated with epoxy resin (TAAB Laboratories Equipment), 
and polymerized at 70°C for 24  h. Semithin sections (0.5 
µm) were cut and stained with 1% Toluidine Blue. Ultrathin 
sections (50–70 nm; Reichert-Jung ultramicrotome) were 
mounted and contrasted using uranyl acetate/lead citrate for 
examination (H7600, 80 kV, AMT digital camera; Hitachi).
For scanning electron microscopy (SEM), pups were 
culled and perfused via the aorta with hPBS before opening 
the femoral and iliac veins and overnight fixation at 4°C in 
glutaraldehyde (2.5% vol/vol in 0.1 M cacodylate buffer, pH 
7.4) and postfixation in 1% (wt/vol) osmium tetroxide for 40 
min at room temperature. After washing, samples were dehy-
drated through graded ethanols before critical point drying 
(Polaron E3000, Quorum Technologies) and mounting with 
conductive carbon cement (TAAB Laboratories Equipment) 
on aluminum pins (TAAB Laboratories Equipment) and gold 
sputter coating (Emitech K550X; Quorum Technologies) for 
examination (S3500N, 20 kV, high vacuum mode; Hitachi). 
VV leaflet length and position were measured in National 
Institutes of Health (NIH) ImageJ software.
Immunohistochemistry
Human. For localization of connexins in human VVs (ob-
tained from patients undergoing coronary artery or lower 
limb bypass grafting), 10-µm frozen sections were thawed and 
fixed in −20°C MeOH before permeabilization in 0.2% Tri-
ton X-100, charge neutralization in 0.5 M NH4Cl, blocking 
in 2% BSA, and incubation with primary antibody. For local-
ization of FOXC2, after fixation in −20°C acetone and 
quenching of endogenous peroxidase using 3% H2O2, block-
ing (X0909; Dako), and incubation with primary antibody, 
signal was amplified using polymer-HRP (MP-XCP; Mena-
rini Group), according to the manufacturer’s instructions. Lo-
calization of integrinα9 was performed on formalin-fixed, 
paraffin-embedded sections, using tyramide amplification 
(PerkinElmer), according to the manufacturer’s instructions.
Mouse. Mice were culled and perfusion fixed via the aorta 
and femoral vein with hPBS, followed by fixation with 4% 
formaldehyde, and then further fixed for 24 h. The external 
iliac and femoral veins were excised with surrounding mus-
cles and processed for paraffin wax embedding and hematox-
ylin-eosin stains. 5-µm sections were photographed using a 
MicroPublisher 3.3 real-time viewing camera mounted on a 
Leitz DMRB microscope with PL Fluotar ×10, ×20, and ×40 
lenses (Leica). Maximum leaflet length of each valve was 
measured in NIH ImageJ.
Whole-mount immunostaining
Mice were culled and perfused with hPBS via the aorta before 
fixation in 4% paraformaldehyde, followed by blocking in 3% 
vol/vol donkey serum in 0.3% Triton X-100. Samples were 
further dissected before incubation with primary antibodies 
and were washed before localization with fluorophore-conju-
gated secondary antibodies. For colocalization of Nfatc1 and 
Foxc2, samples were blocked with Fab (donkey anti-goat IgG 
H + L, 100 µg/ml; Jackson ImmunoResearch Laboratories, 
Inc.) between sequential incubation with antibodies raised 
against Nfatc1 followed by Foxc2. Samples were then fur-
ther dissected and mounted in Prolong Gold (Thermo Fisher 
Scientific). The consistent site of VV formation in unopened 
mouse FV was visualized by confocal microscopy (SP5; 
Leica Biosystems) to produce Z projections (ImageJ; NIH) 
of median filtered (Leica Application Suite Advanced Fluo-
rescence/ImageJ, except for connexin localization) stacks. VV 
Prox1hi nuclear elongation (length/width ratio) and reorien-
tation (relative to the long axis of the vessel) were quantified 
in z-projections in ImageJ, as previously described (Tatin et 
al., 2013). Reorientation was analyzed in nuclei with length/
width ratio ≥2. The position of each nucleus was taken as the 
center of the length measurement, and nuclear centile posi-
tion across the vein was calculated (Excel; Microsoft) and used 
to allocate nuclei into tertiles according to position across the 
vein. For analysis of proliferating VFCs, Prox1hi;Ki-67+ nuclei 
were counted in alternate 1.5 µm optical sections (ImageJ; 
NIH) and presented as a proportion of total Prox1hi VFCs. A 
reduced z-projection (4 slices, 6 µm) is shown (Fig. 5 F).
Antibodies
Immunohistochemistry. Antibodies were raised in rabbits to 
Cx43 (3512; Cell Signaling Technology), sheep to FOXC2 
(AF5044; R&D Systems), Foxc2 (AF6989; R&D Systems), 
and goat to Integrinα9 (BAF3827; R&D Systems).
Whole mount. Antibodies were raised in rabbit to Cx43 
(3512; Cell Signaling Technology), Cx37 (CX37A11; Alpha 
Diagnostics International), Prox1 (11-002P; AngioBio), 
cleaved caspase 3 (9661; Cell Signaling Technology), Ki-67 
(ab15580; Abcam), sheep to Foxc2 (AF6989; R&D Systems), 
goat to Nfatc1 (AF5640; R&D Systems), Prox1 (AF2727; 
R&D Systems), and GFP (ab6658; Abcam) rat to PEC AM1 
(BD clone MEC 13.3) and mouse to α-SMA (clone 1A4 
conjugated to Cy3 [Sigma-Aldrich] or FITC [Abcam]).
signal detection. Secondary antibodies or streptavidin were 
conjugated to Dylight-405/488/550/649 (Jackson Immu-
noResearch Laboratories, Inc.) and streptavidin-HRP/alka-
line phosphatase (Dako). IgG controls were nonimmune 
sheep/rabbit/goat IgG (R&D Systems).
statistical analysis
For human ultrasound, age and sex matching was tested, re-
spectively, by ANO VA (with the Bonferroni correction) and 
Fisher’s exact test. All comparisons of human VV disease phe-
notypes were performed using ANO VA with Bonferroni 
correction. In mice, for VV developmental-stage 0–4 quantifi-
cation, data represent the proportion of analyzed valves reach-
ing each developmental stage. P-values represent differences 
in the proportion of valves at each stage versus WT littermates 
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(χ2/Fisher’s exact test). For quantification of connexin-dele-
tion phenotypes (Fig. 5), the proportion of nuclei elongated 
≥2, and for elongated nuclei, reoriented ≥40°, was compared 
using χ2 tests, as previously described (Tatin et al., 2013).
For analysis of CnB1-deleted VV (Fig. 6), leaflet length 
was compared using a standard template in z-projections (in-
dependent samples t test). VV area was compared using an 
independent-samples t test. Abnormal VV development after 
CsA administration to P6 was compared by χ2 test. For VV 
maintenance, an independent-sample t test was used for two 
groups, and ANO VA was used for three groups. P < 0.05 
was considered significant. All analyses were performed using 
IBM SPSS software (version 22).
online supplemental materials
Further details including patient characteristics, VV variability 
in mouse strains, and individual channels for multi-channel 
images are provided in online supplemental materials. Fig. 
S1 shows the variability in valves in different strains of mice. 
Figs. S2 and S3 show the regulation of initial VV organiza-
tion (Cn–Nfat signaling). Fig. S4 shows the quantification of 
connexin phenotypes. Fig. S5 shows the maturation of leaflets 
and commissures. Table S1 shows the characteristics of study 
participants, and Table S2 shows the number of valves per vein 
in the control group, whereas Table S3 provides leaflet lengths 
per vein in the control group.
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